The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...
The FDA on Thursday expanded the U.S.-approved indications for Bristol-Myers Squibb's (NYSE:BMY) blockbuster immunotherapy ...
The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.
PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...
Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th ...
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback